All In MedTech

FDA Clearance Tracker · P160007-S047

Simplera™ System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 24, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 24, 2024

Approved

Time to decision

525 days

Received Feb 15, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P160007-S047
Device name
Simplera™ System
Applicant location
Northridge, CA
Received
Feb 15, 2023
Decided
Jul 24, 2024
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P160007

Device type

Device class
Class III

Every decision under product code PQF

FDA's approval statement

As written in FDA's record.

Approval for the Simplera system. The Simplera system is a real-time continuous glucose monitoring (CGM) system indicated for the management of diabetes in persons ages 18 years and older. The Simplera system does not require calibration and is designed to replace fingerstick blood glucose (BG) testing for diabetes treatment decisions, unless otherwise indicated. Interpretation of the Simplera system results should be based on the glucose trends and several sequential sensor readings over time.

Source documents

Other decisions for Medtronic Minimed

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.